Similar Search Results

Pricing and Reimbursement in U.S. Pharmaceutical Markets

Berndt, Ernst R.; Newhouse, Joseph P. - 2010

branded pharmaceuticals. We then present a theoretical framework for the pricing of branded pharmaceuticals, without and then …

Persistent link: https://www.econbiz.de/10014191301

External Referencing and Pharmaceutical Price Negotiation

Mariñoso, Begoña; Jelovac, Izabela; Olivella, Pau - 2011

External referencing (ER) imposes a price cap for pharmaceuticals based on prices of identical products in foreign …

Persistent link: https://www.econbiz.de/10014216337

Pharmaceutical Antitrust Complexity

Carrier, Michael A. - 2014

The pharmaceutical industry is unique in its complexity. Markets are nuanced. Multiple regulatory regimes apply. Generic entry is an event with dramatic consequences. These characteristics have encouraged brand-name drug firms to engage in an array of conduct that exploits this complexity to...

Persistent link: https://www.econbiz.de/10014140318

Local Production of Pharmaceutical Products in Africa : The WHO approach

Abbott, Frederick M. - 2014

The WHO Global Strategy and Plan of Action mandated the Director General to support transfer of technology and local production of medicines in developing countries. This paper briefly lays out the conditions for local production in Africa and describes the on-going work program of the WHO...

Persistent link: https://www.econbiz.de/10014143821

Parallel Trade in Pharmaceuticals : Trade Therapy for Market Distortions

Abbott, Frederick M. - 2017

, particularly from an economic standpoint. In this regard, pharmaceuticals are not generally traded in what might be described as a … with the overall regulatory schemes. A drug that is not approved for marketing in a particular country does not become so … because it is imported. Parallel trade (i.e., imports and exports) in pharmaceuticals takes place in markets that are …

Persistent link: https://www.econbiz.de/10014124812

Does Regulation Drive Out Competition in Pharmaceutical Markets?

Danzon, Patricia M.; Chao, Li-Wei - 2011

Most countries regulate pharmaceutical prices, either directly or indirectly, on the assumption that competition is at best weak in this industry. This paper tests the hypothesis that regulation of manufacturer prices and of retail pharmacy margins undermines price competition. We use data from...

Persistent link: https://www.econbiz.de/10014038394

Three Challenges for Pharmaceutical Antitrust

Carrier, Michael A. - 2020

Pharmaceutical antitrust law is hard. When drug companies delay generic entry, is that beneficial “life-cycle management”? Or is it unjustified anti-competitive behavior? The question arises in multiple settings, including patent settlements by which brand firms pay generics to delay...

Persistent link: https://www.econbiz.de/10014107207

Reference Pricing as a Deterrent to Entry : Evidence from the European Pharmaceutical Market

Maini, Luca; Pammolli, Fabio - 2020

External reference pricing (ERP), the practice of benchmarking domestic drug prices to foreign prices, generates an incentive for firms to withhold products from low-income countries. Using a novel moment inequality approach, we estimate a structural model to measure the extent to which ERP...

Persistent link: https://www.econbiz.de/10014093683

Pharmaceutical Marketing : Medical and Industry Biases

Rubin, Paul H. - 2004

positive. The literature written by physicians about pharmaceutical marketing and promotion generally focuses on the harmful …

Persistent link: https://www.econbiz.de/10014029615

Does Entry Remedy Collusion? Evidence from the Generic Prescription Drug Cartel

Starc, Amanda; Wollmann, Thomas - 2022

Entry represents a fundamental threat to cartels engaged in price fixing. We study the extent and effect of this behavior in the largest price fixing case in US history, which involves generic drugmakers. To do so, we link information on the cartel’s internal operations to regulatory filings...

Persistent link: https://www.econbiz.de/10013293949